Answers are grounded in this paper and cite their sources.
Pancreatic cancer remains a highly aggressive malignancy characterized by rapid progression, therapeutic resistance, and poor clinical outcomes, highlighting the need for innovative strategies that improve intracellular drug delivery and target critical survival pathways. The present study investigated a pH-responsive mesoporous silica nanoparticle (MSN) system for encapsulation and delivery of demethylzeylasteral (DMZ), with particular emphasis on modulation of the PI3K/AKT signaling pathway. DMZ-loaded pH-responsive MSNs were prepared and characterized for particle size, polydispersity index, zeta potential, morphology, surface area, pore characteristics, drug-loading efficiency, and structural properties. In vitro release studies were performed under physiological and acidic conditions to evaluate pH-responsive drug release. The biological activity of free DMZ, DMZ-loaded MSNs, and pH-responsive DMZ-MSNs was evaluated in pancreatic cancer cells by assessing cellular uptake, cytotoxicity, apoptosis, cell-cycle distribution, migration, and invasion. Molecular analysis was performed to determine changes in PI3K/AKT/mTOR signaling and apoptosis-associated proteins. The optimized pH-responsive DMZ-MSN formulation demonstrated nanoscale characteristics, efficient DMZ encapsulation, and enhanced drug release under acidic conditions. Compared with free DMZ and non-responsive DMZ-loaded MSNs, the pH-responsive formulation exhibited enhanced cellular uptake, greater cytotoxicity, increased apoptosis, cell-cycle arrest, and stronger inhibition of migration and invasion. These effects were associated with suppression of phosphorylated PI3K, AKT, and mTOR together with increased Bax and cleaved caspase-3 and reduced Bcl-2 expression. In vivo evaluation further indicated enhanced tumor suppression with an acceptable preliminary safety profile. Collectively, the findings support pH-responsive DMZ-MSNs as a promising nanotherapeutic platform for pancreatic cancer targeting PI3K/AKT-associated survival signaling.
No takes yet. Share an insight, caveat, or question.
B et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: